ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

LOX-1 in atherosclerosis: biological functions and pharmacological modifiers

Xu Suowen*; Ogura Sayoko; Chen Jiawei; Little Peter J; Moss Joel; Liu Peiqing复旦大学; NIH
Cellular and Molecular Life Sciences2013-8DOI: 10.1007/s00018-012-1194-z
31被引19阅读
引用收藏
分享

摘要

Lectin-like oxidized LDL (oxLDL) receptor-1 (LOX-1, also known as OLR-1), is a class E scavenger receptor that mediates the uptake of oxLDL by vascular cells. LOX-1 is involved in endothelial dysfunction, monocyte adhesion, the proliferation, migration, and apoptosis of smooth muscle cells, foam cell formation, platelet activation, as well as plaque instability; all of these events are critical in the pathogenesis of atherosclerosis. These LOX-1-dependent biological processes contribute to plaque instability and the ultimate clinical sequelae of plaque rupture and life-threatening tissue ischemia. Administration of anti-LOX-1 antibodies inhibits atherosclerosis by decreasing these cellular events. Over the past decade, multiple drugs including naturally occurring antioxidants, statins, antiinflammatory agents, antihypertensive and antihyperglycemic drugs have been demonstrated to inhibit vascular LOX-1 expression and activity. Therefore, LOX-1 represents an attractive therapeutic target for the treatment of human atherosclerotic diseases. This review aims to integrate the current understanding of LOX-1 signaling, regulation of LOX-1 by vasculoprotective drugs, and the importance of LOX-1 in the pathogenesis of atherosclerosis.

学科与关键词

关键词
AtherosclerosisOxidized LDLLOX-1Soluble LOX-1Review
相关
加载中…
  • LOX-1 Regulation in Anti-atherosclerosis of Active Compounds of Herbal Medicine: Current Knowledge and the New Insight
    Yao Si-jie; Lan Tao-hua; Zhang Xin-yu; Zeng Qiao-huang; Xu Wen-jing; Li Xiao-qing; Huang Gui-bao; Liu Tong; Lyu Wei-hui; Jiang Wei*Chinese Journal of Integrative Medicine, 2023, 29(2): 179-185.被引 1
  • Poly(ADP-ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications
    Xu Suowen*; Bai Peter; Little Peter J; Liu PeiqingMedicinal Research Reviews, 2014, 34(3): 644-675.被引 8
  • Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics
    Jin, Mei; Fang, Jian; Wang, Jiao-jiao; Shao, Xin; Xu, Suo-wen; Liu, Pei-qing*; Ye, Wen-cai*; Liu, Zhi-ping*Acta Pharmacologica Sinica, 2023, 44(12): 2358-2375.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Cellular and Molecular Life Sciences
发表日期
2013-08
卷期
第 70 卷, 第 16 期
页码
2859-2872
DOI
10.1007/s00018-012-1194-z
语言
ENGLISH
期刊等级
Q1
成果收录
SCI
资助标注
National Natural Science Foundation of China [81072641]; NSFC-CIHR CHINA-CANADA Joint Health Research Initiative Proposal [30811120434]; National Science and Technology Major Project of China "Key New Drug Creation and Manufacturing Program'' [2009ZX09102-152, 2011ZX09401-307]; Natural Science Foundation of Guangdong Province [S2011030003190]; Major Project of Guangdong Province [2008A030201013, 2012A080201007]; Major Project of Department of Education of Guangdong Province [CXZD1006]; National Health and Medical Research Council of Australia; National Heart Foundation of Australia; Diabetes Australia Research Trust; Ministry of Education of China

作者

  • X

    Xu Suowen (通讯) (第一作者)

    nih

  • O

    Ogura Sayoko

查看全部 6 位作者收起作者
  • C

    Chen Jiawei

    fudan univ

  • L

    Little Peter J

  • M

    Moss Joel

    nih

  • L

    Liu Peiqing

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417